Co-authors (11)

Embed

Academic

Authors

Holger Fuchs

Holger Fuchs,Aalborg University,Medicinal Chemistry

Edit

Holger Fuchs

Aalborg University

Publications: 1 | Citations: 13

Fields: Medicinal Chemistry

Collaborated with 11 co-authors in 2007 | Cited by 48 authors

Cumulative Annual

Sort by:

Publications (1)

BibTeX | RIS | RefWorks Download

8-(3-( R )-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a Highly Potent, Selective, Long-Acting, and Orally Bioavailable DPP-4 Inhibitor for the Treatment of Type 2 Diabetes † (Citations: 13)

, , , , , , , , , , ,

Journal: Journal of Medicinal Chemistry - J MED CHEM , vol. 50, no. 26, pp. 6450-6453, 2007

Sort by:

Citations (13 times by 13 publications)

The pharmacological landscape and therapeutic potential of serine hydrolases

Journal: Nature Reviews Drug Discovery - NAT REV DRUG DISCOV , vol. 11, no. 1, pp. 52-68, 2012

Letter to the Editor re: “The effect of non-steroidal anti-inflammatory agents on behavioural changes and cytokine production following systemic inflammation: Implications for a role of COX1.” by Teeling et al

, , , ,

Journal: Brain Behavior and Immunity - BRAIN BEHAV IMMUN , vol. 25, no. 3, pp. 584-585, 2011

Evaluation of the pharmacokinetic interaction after multiple oral doses of linagliptin and digoxin in healthy volunteers

, , , , ,

Journal: European Journal of Drug Metabolism and Pharmacokinetics - EUR J DRUG METAB PHARM , vol. 36, no. 1, pp. 17-24, 2011

In vitro and in vivo behaviors of dextran functionalized graphene

, , ,

Journal: Carbon , vol. 49, no. 12, pp. 4040-4049, 2011

New directions in linking the dynamics of affective and stress-arousal systems

Journal: Brain Behavior and Immunity - BRAIN BEHAV IMMUN , vol. 25, no. 2, pp. 230-231, 2011

Comments

Co-authors (11)

Journals (1)

Keywords (1)

Holger Fuchs,Aalborg University,Medicinal Chemistry

Publications (1)

BibTeX | RIS | RefWorks Download

8-(3-( R )-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a Highly Potent, Selective, Long-Acting, and Orally Bioavailable DPP-4 Inhibitor for the Treatment of Type 2 Diabetes † (Citations: 13)

Citations (13 times by 13 publications)

The pharmacological landscape and therapeutic potential of serine hydrolases

Letter to the Editor re: “The effect of non-steroidal anti-inflammatory agents on behavioural changes and cytokine production following systemic inflammation: Implications for a role of COX1.” by Teeling et al

Evaluation of the pharmacokinetic interaction after multiple oral doses of linagliptin and digoxin in healthy volunteers

In vitro and in vivo behaviors of dextran functionalized graphene

New directions in linking the dynamics of affective and stress-arousal systems


	View FAQ about top research areas and Fields of study

Holger Fuchs,Aalborg University,Medicinal Chemistry

Publications (1) BibTeX | RIS | RefWorks Download

8-(3-( R )-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a Highly Potent, Selective, Long-Acting, and Orally Bioavailable DPP-4 Inhibitor for the Treatment of Type 2 Diabetes † (Citations: 13)

Publications (1)

BibTeX | RIS | RefWorks Download